{"contentid": 488589, "importid": NaN, "name": "Sumitomo Dainippon acquires Asian rights for Sinovant compounds", "introduction": "Japanese pharma company Sumitomo Dainippon Pharma is to acquire the exclusive development and marketing rights in China, Hong Kong, Taiwan and other Asian markets for multiple development compounds from Sinovant, a subsidiary of Roivant Sciences.", "content": "<p>Japanese pharma company Sumitomo Dainippon Pharma (TYO: 4506) is to acquire the exclusive development and marketing rights in China, Hong Kong, Taiwan and other Asian markets for multiple development compounds from Sinovant, a subsidiary of Roivant Sciences.</p>\n<p>Under the terms of the agreement, Sinovant will assign the license agreement for lefamulin with Nabriva Therapeutics to Sumitomo, which will, in turn, acquire the exclusive development and marketing rights in Greater China for the pleuromutilin antimicrobial agent.</p>\n<p><span class=\"pullQuote\">\"Sumitomo expects the development assets to contribute to its sustained growth in China and other Asian markets\"</span></p>\n<p>Sumitomo will also acquire the rights in China for vibegron, RVT-802 and rodatristat ethyl from Sinovant.</p>\n<p>Lefamulin has been approved for the indication of community-acquired bacterial pneumonia in adults by the US Food and Drug Administration (FDA), Health Canada and the European Medicines Agency. It is currently being marketed in the USA under the brand name Xenleta. A Phase III study is currently being conducted in China for community-acquired bacterial pneumonia.</p>\n<p>Vibegron is an oral, once-daily, small molecule &beta;3 adrenergic receptor agonist. Urovant Sciences, a consolidated subsidiary of Sumitomo, obtained the approval for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults from the FDA in December 2020. The drug is currently being marketed by Urovant in the USA under the brand name Gemtesa. A development plan in China is currently being evaluated.</p>\n<p>RVT-802, a one-time regenerative therapy, is cultured human thymus tissue engineered to generate a functioning immune response when implanted in pediatric patients with congenital athymia. In the USA, Enzyvant Therapeutics, a consolidated subsidiary of Sumitomo, has resubmitted the Biologics Licensing Application to the FDA for RVT802, for pediatric congenital athymia, in April 2021.</p>\n<p>Again, a development plan for RVT802 in China is currently being evaluated, as it is for rodatristat ethyl, a prodrug of tryptophan hydroxylase inhibitor designed to reduce peripheral production of serotonin without entering the brain. In the USA, Altavant Sciences, another consolidated subsidiary of Sumitomo, is conducting a Phase IIb study of the candidate in pulmonary arterial hypertension.</p>\n<p>Under a strategic alliance agreement concluded with Roivant in 2019, Sumitomo obtained options to acquire ownership interests in six of its subsidiaries, including Sinovant and Genevant Sciences.</p>\n<p>Sumitomo will now terminate its five remaining options to acquire Roivant&rsquo;s ownership interest in its subsidiaries as part of this transaction. In addition, it will make a payment to Sinovant as consideration for the agreement.</p>\n<p>The Osaka-based company has also agreed to enter into an agreement with respect to certain potential future collaborations on lipid nanoparticle development programs with Genevant.</p>\n<p>A Sumitomo statement explains that the company &ldquo;will strive to further contribute to the treatment of infectious diseases in China and other parts of Asia by adding lefamulin to the infectious disease area that Sumitomo Pharmaceuticals is focusing on.&rdquo;</p>\n<p>The statement adds: &ldquo;Sumitomo Dainippon Pharma also expects the three development assets that will be acquired under the agreement to contribute to its sustained growth in China and other Asian markets, with contribution to a greater number of patients in China and other parts of Asia.&rdquo;</p>", "date": "2021-05-10 18:00:00", "meta_title": NaN, "meta_keywords": "Sumitomo, development, China, Sinovant, Asian, rights, pharma, acquire, Dainippon, subsidiary, Sciences, compounds, markets, agreement, company, marketing", "meta_description": "Japanese pharma company Sumitomo Dainippon Pharma is to acquire the exclusive development and marketing rights in China, Hong Kong, Taiwan and other Asian marke", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-10 17:48:15", "updated": "2021-05-10 19:14:32", "access": NaN, "url": "https://www.thepharmaletter.com/article/sumitomo-dainippon-acquires-asian-rights-for-sinovant-compounds", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "dainippon-big.jpg", "image2id": "dainippon-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Antibiotics, Cardio-vascular, Infectious diseases, Neurological, Rare diseases, Respiratory and Pulmonary", "topic_tag": "Asia Pacific, Deals, Focus On, Licensing", "geography_tag": "China, Japan", "company_tag": "Altavant Sciences, Enzyvant Sciences, Genevant Sciences, Roivant Sciences, Sinovant Sciences, Sumitomo Dainippon Pharma, Urovant Sciences Ltd", "drug_tag": "lefamulin, rodatristat ethyl, RVT-802, vibregon", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-10 18:00:00"}